Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A phase 1/2 trial interim update shows that DB107-RRV, a retroviral vector injected directly into brain tumor cavities, can be safely combined with radiation and the prodrug DB107-FC in newly diagnosed high-grade glioma patients. Of 28 evaluable patients, 16 remained on treatment, with some lasting over a year. Side effects were largely consistent with standard chemoradiation.
A new interim update from a phase 1/2 trial (NCT06504381) offers encouraging early signs for a novel gene therapy approach in newly diagnosed high-grade glioma (HGG) — one of the most aggressive and difficult-to-treat brain cancers. The regimen combines DB107-RRV (vocimagene amiretrorepvec), a retroviral vector injected into the walls of the surgical tumor cavity and given intravenously, with the prodrug DB107-FC, alongside standard radiation with or without temozolomide.
Of 28 evaluable patients across 5 sites, 16 remained on treatment at the October 2026 data cutoff. The longest treatment duration reached 618 days, and 4 patients had been on therapy for over a year — a notable signal in a disease where outcomes are typically poor. Discontinuations were mostly due to disease progression, and the safety profile was largely consistent with standard chemoradiation.
By the Numbers:
Why it matters: High-grade glioma carries a grim prognosis with limited treatment options. This trial's early durability signals and manageable safety profile suggest DB107-RRV could be a viable addition to the treatment arsenal — with biomarker work (DGM7, transcriptomics) underway to identify which patients benefit most.